Loading organizations...
§ Private Profile · Boston, MA, USA
Scorpion Therapeutics is a technology company.
Scorpion Therapeutics has raised $420.0M across 3 funding rounds.
Key people at Scorpion Therapeutics.
Scorpion Therapeutics has raised $420.0M in total across 3 funding rounds.
Scorpion is a clinical-stage, precision oncology company developing transformational targeted therapies for patients with cancer. We have built proprietary and fully-integrated discovery capabilities leveraging the most advanced technologies across cancer biology, medicinal chemistry and data sciences.
Key people at Scorpion Therapeutics.
Scorpion Therapeutics has raised $420.0M across 3 funding rounds. Most recently, it raised $150.0M Series C in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2024 | $150M Series C | Frazier Life Sciences, Lightspeed Venture Partners | Atlas Venture, Frazier Healthcare Partners, General Atlantic, Krishna Yeshwant, Polaris Partners, RA Capital, SR ONE, Vida Ventures, Josh Resnick | Announced |
| Jan 1, 2021 | $160M Series B | Vida Ventures, Boxer Capital, EcoR1 Capital, Omega Funds | Atlas Venture, General Atlantic, Krishna Yeshwant, Polaris Partners, RA Capital, SR ONE, Josh Resnick | Announced |
| Oct 1, 2020 | $110M Series A | Atlas Venture, Vida Ventures, Omega Funds | General Atlantic, Krishna Yeshwant, Polaris Partners, RA Capital, SR ONE, Josh Resnick | Announced |
Scorpion Therapeutics has raised $420.0M in total across 3 funding rounds.
Scorpion Therapeutics's investors include Frazier Life Sciences, Lightspeed Venture Partners, Atlas Venture, Frazier Healthcare Partners, General Atlantic, Krishna Yeshwant, Polaris Partners, RA Capital, SR One, Vida Ventures, Josh Resnick, Boxer Capital.
Scorpion Therapeutics is a clinical-stage precision oncology company developing targeted small-molecule drugs to expand precision medicine's reach to more cancer patients.[1][2][4] Founded in 2020 and based in Boston with offices in San Francisco, it integrates cutting-edge technologies in target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, addressing limitations of current treatments by targeting validated cancer drivers with greater selectivity, safety, and efficacy.[1][2][4] The company serves cancer patients, particularly those with breast cancer, solid tumors, EGFR-mutant non-small-cell lung cancer (NSCLC), and others underserved by existing therapies, solving the problem that fewer than 10% of patients currently benefit from precision therapies through its proprietary, target-centric discovery platform.[4][5][6]
Scorpion has shown strong growth momentum, launching with $108 million in 2021, forming major partnerships like a $75 million alliance with AstraZeneca and a collaboration with Pierre Fabre for EGFR programs, and advancing candidates like STX-478 (a mutant-selective PI3Kα inhibitor) to clinical trials in under 2.5 years despite COVID challenges.[3][4][6][7] By 2025, its lead program STX-478 was acquired by Eli Lilly in a deal valued at up to $2.5 billion, marking a major validation of its platform.[5][6]
Scorpion Therapeutics was co-founded in 2020 by Keith Flaherty, M.D., an international expert in targeted therapies and serial entrepreneur; Liron Bar-Peled, and Gaddy Getz, amid the early COVID-19 pandemic.[4] The idea emerged from a recognition that precision oncology needed acceleration: only ~10% of patients benefit from current therapies, prompting the team to build an integrated platform combining genomics, data sciences, and chemistry to rapidly validate and drug "well-validated targets" with clear precision hypotheses.[4]
Early traction was swift despite pandemic hurdles—the company raised $108 million at launch, advanced two candidates to IND-enabling studies in 2.5 years, and built a 90-person team across Boston and San Francisco.[2][3][4] Leadership includes experienced executives like CEO Axel Hoos, M.D., and CSO Adam Friedman, M.D., Ph.D., executing a "fit-to-purpose" model.[1][4][6]
Scorpion rides the precision oncology wave, leveraging advances in genomics and AI-driven drug discovery to target "undruggable" or underserved cancer drivers, amid a market where precision therapies are expanding but still reach <10% of patients.[1][4] Timing is ideal post-COVID, with biopharma's push for faster, data-integrated R&D; market forces like rising cancer incidence and big pharma's oncology M&A (e.g., Lilly's $2.5B deal, AstraZeneca alliance) favor its model.[4][5][6]
It influences the ecosystem by validating target-centric biotech, inspiring integrated platforms that de-risk development and attract partnerships, while pushing PI3K/EGFR innovations despite historical setbacks.[4][5][6][7]
With STX-478's acquisition by Eli Lilly, Scorpion's remaining pipeline and platform position it for continued impact, potentially through spin-outs, new funding, or further deals in EGFR/PI3K space.[5][6] Trends like AI-genomics integration and oncology M&A will shape its path, evolving its influence from pioneer to ecosystem shaper in Precision Oncology 2.0. This validates its mission to broaden precision medicine, fulfilling the promise that hooked investors from day one.[1][4][5]
